Objective: To develop an ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of 15 bile acids in Babaodan, and different batches of Babaodan samples were evaluated. Methods: Chromatographic separation was performed on a CORTECS®UPLC® C18 column (100 mm×2.1 mm, 1.6 μm) with mobile phaseconsisting of acetonitrile-methanol solution (1∶1) and 0.1% formic acid solution at a flow rate of 0.2 mL·min-1 using gradient elution, and the column temperature was 45 ℃. MS monitoring was performed by electrospray ionization in positive and negative ion switching mode using multiple reaction monitoring. SPSS software was employed to perform the hierarchical cluster analysis and box chart analysis for the content determination results. Results: The calibration curves for 15 bile acids had good linearity (r≥0.996 4) in their linear range. The RSDs of precision, repeatability, and stability were all less than 7.3%, the average recoveries were in the range of 85.6%-105.1% (RSD≤9.7%). The content ranges of ursodeoxycholic acid, hyodeoxycholic acid, chenodeoxycholic acid, deoxycholic acid, cholic acid, lithocholic acid, taurochenodeoxycholic acid, taurohyodeoxycholic acid, tauroursodeoxycholic acid, taurocholic acid, glycocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, taurolithocholic acid and taurodexycholic acid in 11 batches of Babaodan were 0.003 8-0.010 9, 0.139 9-0.695 2, 1.917 6-4.166 0, 2.115 4-6.346 2, 11.058 5-25.361 4, 0.116 8-0.294 5, 0.000 6-0.003 8, 0.002 6-0.093 6, 0.035 4-0.194 2, 2.612 5-8.187 2, 0.190 6-6.718 3, 0.326 6-1.915 3, 0.006 0-0.530 9, 0.007 0-0.040 000 and 0.517 3-1.981 8 mg·g-1, respectively. Hierarchical cluster analysis classified 11 batches of Babaodan into 2 categories, sample S1-S7 in category Ⅰ and sample S8-S11 in category Ⅱ. The results of box chart analysis showed that there were significant differences in the internal quality of Babaodan from different production batches. Conclusion: The method developed in this study can quickly achieve qualitative and quantitative detection of 15 bile acids in Babaodan, which can be used in the quality evaluation of Babaodan.
[1] 盛洪达, 李洪祥, 关斌, 等. 基于网络药理学和分子对接的八宝丹治疗病毒性肝炎潜在机制研究[J].上海中医药大学学报, 2021, 35(1): 93
SHENG HD, LI HX, GUAN B, et al. Potential mechanism of Babao Pill in treatment of viral hepatitis based on network pharmacology and molecular docking[J].Acad J Shanghai Univ Tradit Chin Med, 2021, 35(1): 93
[2] 关建华, 靳祎祎, 庄群川, 等. 八宝丹对人脐静脉内皮细胞增殖和迁移的影响[J].福建中医药, 2018, 49(3): 64
GUAN JH, JIN YY, ZHUANG QC, et al. Effect of Babao Dan on proliferation and migration of human umbilical vein endothelial cells[J].Fujian J Tradit Chin Med, 2018, 49(3): 64
[3] WANG Q, LIU Z, DU K, et al. Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells[J].Am J Transl Res, 2019, 11(8): 5272
[4] SONG LB, GAO S, ZHANG AQ, et al. Babaodan Capsule combined with Qingyi Huaji Formula in advanced pancreatic cancer-a feasibility study[J].Chin J Integr Med, 2017, 23(12): 937
[5] SHENG DD, ZHAO SM, GAO L, et al. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling[J].Cell Biosci, 2019, 9: 77
[6] LU L, WU C, LU BJ, et al. BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats[J].J Ethnopharmacol, 2020, 249: 112301
[7] QIAN J, XU HD, LV DQ, et al. Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment[J].Biomed Pharmacother, 2021, 139: 111586
[8] 陈曦, 武超, 孙润菲, 等. 八宝丹治疗肝病临床研究进展[J].中华中医药学刊, 2017, 35(5): 1215
CHEN X, WU C, SUN RF, et al. Clinical research progress of Babaodan in treatment of liver disease[J].Chin Arch Tradit Chin Med, 2017, 35(5): 1215
[9] 陆璐. 八宝丹防治肝性脑病的效应机制研究[D].上海: 上海中医药大学, 2019
LU L. Research on the Preventive and Therapeutic Effect of Babaodan on Hepatic Encephalopathy in Rats[D].Shanghai: Shanghai University of Traditional Chinese Medicine, 2019
[10] 赵娜萍. 八宝丹对原发性肝癌和脂肪肝的影响及机制研究[D].上海: 第二军医大学, 2017
ZHAO NP. Effect and Mechanism of Babaodan on Primary Hepatocellular Carcinoma and Fatty Liver[D].Shanghai: Naval Medical University, 2017
[11] 刘建鑫, 尚海霞, 杨弘, 等. 八宝丹抑制胃癌细胞转移的作用研究[J].福建中医药, 2018, 49(2): 62
LIU JX, SHANG HX, YANG H, et al. Study on the inhibitory effect of Babaodan on metastasis of gastric cancer cells[J].Fujian J Tradit Chin Med, 2018, 49(2): 62
[12] 沈美蓉, 裴彬, 李仲平. 八宝丹胶囊治疗黄疸型病毒性肝炎临床研究[J].河北中医, 2012, 34(4): 492
SHEN MR, PEI B, LI ZP. Clinical study of Babaodan capsules in treating jaundice viral hepatitis[J].Hebei J Tradit Chin Med, 2012, 34(4): 492
[13] 李洪伦, 刘瑾瑜, 耿军祖, 等. 八宝丹在恶性肿瘤治疗中的应用探索[J].滨州医学院学报, 2016, 39(5): 383
LI HL, LIU JY, GENG JZ, et al. Application and exploration of Babao Dan in the treatment of malignant tumors[J].J Binzhou Med Univ, 2016, 39(5): 383
[14] 黄彬, 白雪松, 彭军, 等. 八宝丹基础和临床应用研究进展[J].福建中医药, 2018, 49(1): 83
HUANG B, BAI XS, PENG J, et al. Research progress on basic and clinical application of Babao Dan[J].Fujian J Tradit Chin Med, 2018, 49(1): 83
[15] CHENG Z, ZHUO S, GUO S, et al. Quantification and discovery of quality control chemical markers for Ba-Bao-Dan by UPLC-MS/MS combined with chemometrics[J].J Pharm Biomed Anal, 2021, 204: 114273
[16] 李洋, 余静, 赵亚红, 等. 中药复方制剂八宝丹中化学成分的UHPLC-Q-TOF/MS分析[J].第二军医大学学报, 2016, 37(12): 1548
LI Y, YU J, ZHAO YH, et al. UHPLC-Q-TOF-MS in analyzing chemical constituents of traditional Chinese herbal perparation BabaoDan[J].Acad J Nav Med Univ, 2016, 37(12): 1548
[17] 袁斌, 任颖龙, 马莉, 等. 胆汁酸类成分替代中药熊胆的药性分析[J].中国中药杂志, 2014, 39(4): 738
YUAN B, REN YL, MA L, et al. Analysis on replacement of traditional Chinese medicine bear bile with bile acids based on drug properties[J].China J Chin Mater Med, 2014, 39(4): 738
[18] 刘欣媛, 李培锋. 牛磺胆酸研究进展[J].包头医学院学报, 2010, 26(4): 134
LIU XY, LI PF. Research progress on taurocholate acid[J].J Baotou Med Coll, 2010, 26(4): 134
[19] LIU XS, WU ZZ, YANG K, et al. Quantitative analysis combined with chromatographic fingerprint for comprehensive evaluation of Danhong injection using HPLC-DAD[J].J Pharm Biomed Anal, 2013, 76: 70
[20] 尚婵, 李孟璇, 李海波, 等. LC-MS/MS同时测定痛安注射液中13个成分的含量[J].中国中药杂志, 2017, 42(10): 1901
SHANG C, LI MX, LI HB, et al. Simultaneous determination of thirteen components in Tong’an injection by LC-MS/MS[J].China J Chin Mater Med, 2017, 42(10): 1901
[21] 陈星玲, 宿树兰, 刘睿, 等. 胆汁类动物药中胆汁酸化学成分和药理作用研究进展[J].中国中药杂志, 2021, 46(19): 4898
CHEN XL, SU SL, LIU R, et al. Research progress on chemical constituents and pharmacological action of bile acids in bile animal drugs[J].China J Chin Mater Med, 2021, 46(19): 4898
